2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K, Pagani O, Partridge A, Pritchard K, Ro J, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals Of Oncology 2017, 28: 1700-1712. PMID: 28838210, PMCID: PMC6246241, DOI: 10.1093/annonc/mdx308.Peer-Reviewed Original ResearchConceptsLow-risk patientsBreast cancerNeoadjuvant therapyPostmenopausal womenEarly-stage breast cancerER-positive breast cancerAvoidance of chemotherapyDe-escalate therapyAdjuvant endocrine treatmentRegional nodal irradiationHigh-risk patientsEarly breast cancerSentinel node biopsyHigh-risk tumorsPositive breast cancerBreast cancer recurrenceExpert consensus conferenceSubstantial new evidenceNodal irradiationBisphosphonate useEndocrine treatmentNeoadjuvant treatmentOvarian suppressionPremenopausal womenPrimary therapy
2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
Kimmick G, Cirrincione C, Duggan D, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson I, Hudis C, Winer E, On Behalf of the Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Research And Treatment 2008, 113: 479-490. PMID: 18306034, PMCID: PMC4217205, DOI: 10.1007/s10549-008-9943-2.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDisease ProgressionDoxorubicinFemaleFluorouracilFollow-Up StudiesHumansMastectomyMethotrexateMiddle AgedNeoadjuvant TherapyNeoplasm StagingRadiotherapy, AdjuvantSurvival AnalysisConceptsStage III breast cancerBreast cancerNeoadjuvant doxorubicinClinical responseLymph nodesClinical stage III breast cancerAdequate organ functionClinical response rateComplete clinical responseInvolved lymph nodesPositive lymph nodesAdvanced breast cancerPathologic complete responsePhase II trialHazard of deathLong-term resultsLong-term survivalAdjuvant chemotherapyAdjuvant cyclophosphamideMedian followII trialNeoadjuvant treatmentMultimodality treatmentOverall survivalComplete response